{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:42:58Z","timestamp":1784860978533,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00259-025-07431-8","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:44:35Z","timestamp":1751949875000},"page":"350-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased incidence of primary metastatic prostate cancer in the era of PSMA PET\/CT: a population-based analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-4258","authenticated-orcid":false,"given":"B. L.","family":"Heesterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K.H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. S.C.","family":"Eppinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"7431_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"7431_CR2","unstructured":"https:\/\/www.iknl.nl\/nkr-cijfers"},{"key":"7431_CR3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.ejca.2010.03.040","volume":"46","author":"RG Cremers","year":"2010","unstructured":"Cremers RG, Karim-Kos HE, Houterman S, Verhoeven RH, Schroder FH, van der Kwast TH, et al. Prostate cancer: trends in incidence, survival and mortality in the netherlands, 1989\u20132006. Eur J Cancer. 2010;46:2077\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2010.03.040.","journal-title":"Eur J Cancer"},{"key":"7431_CR4","unstructured":"de Reijke TM, Barentsz JO, Coenen JLLM, van der Giessen R, Gietema JA, Incrocci L et al. Module PSMA PET \/ CT voor de richtlijn Prostaatcarcinoom. Nederlandse Vereniging voor Urologie. 2019. pp. 1\u201340."},{"key":"7431_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate Cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185\u201390. https:\/\/doi.org\/10.2967\/jnumed.115.160382.","journal-title":"J Nucl Med"},{"key":"7431_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ van Leeuwen","year":"2016","unstructured":"van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. 68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117:732\u20139. https:\/\/doi.org\/10.1111\/bju.13397.","journal-title":"BJU Int"},{"key":"7431_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2015;56:668\u201374. https:\/\/doi.org\/10.2967\/jnumed.115.154153.","journal-title":"Soc Nuclear Med"},{"key":"7431_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","volume":"46","author":"F Ceci","year":"2019","unstructured":"Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, et al. (68)Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019;46:31\u20139. https:\/\/doi.org\/10.1007\/s00259-018-4189-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7431_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective Single-Arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"7431_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"7431_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","volume":"48","author":"BHE Jansen","year":"2021","unstructured":"Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, et al. Pelvic lymph-node staging with (18)F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Eur J Nucl Med Mol Imaging. 2021;48:509\u201320. https:\/\/doi.org\/10.1007\/s00259-020-04974-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7431_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate Cancer patients (OSPREY). J Urol. 2021;206:52\u201361. https:\/\/doi.org\/10.1097\/JU.0000000000001698.","journal-title":"J Urol"},{"key":"7431_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/JU.0000000000000531","volume":"203","author":"LWM van Kalmthout","year":"2020","unstructured":"van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, et al. Prospective validation of Gallium-68 prostate specific membrane Antigen-Positron emission tomography\/computerized tomography for primary staging of prostate Cancer. J Urol. 2020;203:537\u201345. https:\/\/doi.org\/10.1097\/JU.0000000000000531.","journal-title":"J Urol"},{"key":"7431_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","volume":"36","author":"J Corfield","year":"2018","unstructured":"Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36:519\u201327. https:\/\/doi.org\/10.1007\/s00345-018-2182-1.","journal-title":"World J Urol"},{"key":"7431_CR15","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7431_CR16","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer G, De Santis M et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. European Association of Urology Guidelines; 2025."},{"key":"7431_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","volume":"82","author":"K De Man","year":"2022","unstructured":"De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, et al. (18)F-PSMA-11 versus (68)Ga-PSMA-11 positron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: A prospective Double-blind randomised Cross-over trial. Eur Urol. 2022;82:501\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.010.","journal-title":"Eur Urol"},{"key":"7431_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.eururo.2022.06.001","volume":"82","author":"PJ van Leeuwen","year":"2022","unstructured":"van Leeuwen PJ, Emmett L. (18)F-PSMA-11 as an attractive (68)Ga-PSMA-11 alternative for prostate Cancer imaging. Eur Urol. 2022;82:510\u20131. https:\/\/doi.org\/10.1016\/j.eururo.2022.06.001.","journal-title":"Eur Urol"},{"key":"7431_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. (18)F-Labeled, PSMA-Targeted radiotracers: leveraging the advantages of radiofluorination for prostate Cancer molecular imaging. Theranostics. 2020;10:1\u201316. https:\/\/doi.org\/10.7150\/thno.37894.","journal-title":"Theranostics"},{"key":"7431_CR20","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","volume":"312","author":"AR Feinstein","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK. The will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604\u20138. https:\/\/doi.org\/10.1056\/NEJM198506203122504.","journal-title":"N Engl J Med"},{"key":"7431_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2018;59:82\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.197160.","journal-title":"J Nucl Med"},{"key":"7431_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","volume":"48","author":"M Wondergem","year":"2021","unstructured":"Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, et al. (18)F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. Eur J Nucl Med Mol Imaging. 2021;48:521\u201331. https:\/\/doi.org\/10.1007\/s00259-020-04782-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7431_CR23","volume-title":"TNM classification of malignant tumours. Eighth edition ed. Chichester","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Eighth edition ed. Chichester. West Sussex, UK; Hoboken, NJ: Wiley Blackwell; 2017."},{"key":"7431_CR24","volume-title":"Revision of the European standard population: report of eurostat\u2019s task force: 2013 edition","author":"E European Commission","year":"2013","unstructured":"European Commission E. Revision of the European standard population: report of eurostat\u2019s task force: 2013 edition. LU: Publications Office; 2013."},{"key":"7431_CR25","unstructured":"Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research. IV. Descriptive epidemiology. IARC Sci Publ. 1994. pp. 1\u2013302."},{"key":"7431_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","volume":"57","author":"A Briganti","year":"2010","unstructured":"Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol. 2010;57:551\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.023.","journal-title":"Eur Urol"},{"key":"7431_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","volume":"75","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate Cancer diagnosed with magnetic resonance Imaging-targeted and systematic biopsies. Eur Urol. 2019;75:506\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.012.","journal-title":"Eur Urol"},{"key":"7431_CR28","unstructured":"Yoshida K, Bartel A, tableone. Create \u2018Table 1\u2019 to Describe Baseline Characteristics with or without Propensity Score Weights. 2022."},{"key":"7431_CR29","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.ctarc.2022.100553","volume":"31","author":"DV Deukeren","year":"2022","unstructured":"Deukeren DV, Heesterman BL, Roelofs L, Kiemeney LA, Witjes JA, Smilde TJ, et al. Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. Cancer Treat Res Commun. 2022;31:100553. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100553.","journal-title":"Cancer Treat Res Commun"},{"key":"7431_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13629-021-00318-x","volume":"11","author":"BL Heesterman","year":"2021","unstructured":"Heesterman BL, Olthof EMG, van der Poel HG, van Moorselaar RJA, Aben KKH. Kwaliteitsregistratie prostaatcarcinoom: ziekenhuisregistratie versus nederlandse kankerregistratie. Tijdschrift Voor Urologie. 2021;11:34\u201343. https:\/\/doi.org\/10.1007\/s13629-021-00318-x.","journal-title":"Tijdschrift Voor Urologie"},{"key":"7431_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrurol.2016.251","volume":"14","author":"K Fleshner","year":"2017","unstructured":"Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14:26\u201337. https:\/\/doi.org\/10.1038\/nrurol.2016.251.","journal-title":"Nat Rev Urol"},{"key":"7431_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bju.12029","volume":"112","author":"S Van der Meer","year":"2013","unstructured":"Van der Meer S, Kollen BJ, Hirdes WH, Steffens MG, Hoekstra-Weebers JE, Nijman RM, et al. Impact of the European randomized study of screening for prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. BJU Int. 2013;112:26\u201331. https:\/\/doi.org\/10.1111\/bju.12029.","journal-title":"BJU Int"},{"key":"7431_CR33","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1001\/jama.2015.14905","volume":"314","author":"A Jemal","year":"2015","unstructured":"Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314:2054\u201361. https:\/\/doi.org\/10.1001\/jama.2015.14905.","journal-title":"JAMA"},{"key":"7431_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/JU.0000000000000595","volume":"203","author":"H Goldberg","year":"2020","unstructured":"Goldberg H, Ahmad AE, Chandrasekar T, Klotz L, Emberton M, Haider MA, et al. Comparison of magnetic resonance imaging and transrectal ultrasound informed prostate biopsy for prostate Cancer diagnosis in biopsy Naive men: A systematic review and Meta-Analysis. J Urol. 2020;203:1085\u201393. https:\/\/doi.org\/10.1097\/JU.0000000000000595.","journal-title":"J Urol"},{"key":"7431_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","volume":"147","author":"TFW Soeterik","year":"2021","unstructured":"Soeterik TFW, van Melick HHE, Dijksman LM, Biesma DH, Witjes JA, van Basten JA. Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate Cancer local staging and disease risk classification. Urology. 2021;147:205\u201312. https:\/\/doi.org\/10.1016\/j.urology.2020.08.089.","journal-title":"Urology"},{"key":"7431_CR36","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"key":"7431_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard First-Line therapy in metastatic prostate Cancer. N Engl J Med. 2019;381:121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"key":"7431_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"key":"7431_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate Cancer. N Engl J Med. 2017;377:352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"key":"7431_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic Hormone-Sensitive prostate Cancer. N Engl J Med. 2015;373:737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"key":"7431_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5.","journal-title":"Lancet"},{"key":"7431_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2020.07.029","volume":"79","author":"N Sundahl","year":"2021","unstructured":"Sundahl N, Gillessen S, Sweeney C, Ost P. When what you see is not always what you get: Raising the bar of evidence for new diagnostic imaging modalities. Eur Urol. 2021;79:565\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.029.","journal-title":"Eur Urol"},{"key":"7431_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.024","author":"A Varatharajan","year":"2023","unstructured":"Varatharajan A, Olivier T, Prasad V. Prostate-specific membrane antigen positron emission tomography in the staging of newly diagnosed prostate cancer: is more sensitivity always better?? Eur Urol. 2023. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.024.","journal-title":"Eur Urol"},{"key":"7431_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23. https:\/\/doi.org\/10.1186\/s40644-020-00300-7.","journal-title":"Cancer Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07431-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07431-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07431-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:06:03Z","timestamp":1764219963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07431-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7431"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07431-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Dutch law, approval of an institutional ethics committee was not required. This study was approved by the Privacy Review Board of the NCR (K20.314\/25-00998).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial interests to disclose. D.E. Oprea-Lager is chair of the PSMA Forum NL Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0"}}]}}